Purpose: To investigate the feasibility and efficacy of 25-gauge vitrectomy in the treatment of proliferative diabetic retinopathy (PDR). Methods: All patients underwent primary 25-gauge vitrectomy for simple vitreous hemorrhage (VH), fibrovascular proliferation (FVP), or tractional retinal detachment (TD), and were followed for more than 1 month. Final visual outcomes and intraoperative and postoperative complications were evaluated. Results: 167 eyes (138 patients) were used in this study, 65 eyes (39%) with VH, 66 eyes (40%) with FVP, and 36 eyes (21%) with TD. Measured using the mean logarithm of the minimum angle of resolution (logMAR), visual acuity (VA) significantly improved (p < 0.0001). Intraoperative iatrogenic retinal breaks developed in 19 eyes (11%). Concerning postoperative complications, VH in 36 eyes (22%), retinal detachment in 2 eyes (1%), and neovascular glaucoma 12 eyes (7%) were observed. No endophthalmitis developed. Conclusions: Twenty-five-gauge vitrectomy can successfully treat PDR. Clinical outcomes and complications are comparable to those of 20-gauge vitrectomy.

1.
Fujii GY, De Juan E Jr, Humayun MS, Pieramici DJ, Chang TS, Awh C, Ng E, Barnes A, Wu SL, Sommerville DN: A new 25-gauge instrument system for transconjunctival sutureless vitrectomy surgery. Ophthalmology 2002;109:1807–1812.
2.
Lakhanpal RR, Humayun MS, de Juan E Jr, Lim JI, Chong LP, Chang TS, Javaheri M, Fujii GY, Barnes AC, Alexandrou TJ: Outcomes of 140 consecutive cases of 25-gauge transconjunctival surgery for posterior segment disease. Ophthalmology 2005;112:817–824.
3.
Ibarra MS, Hermel M, Prenner JL, Hassan TS: Longer-term outcomes of transconjunctival sutureless 25-gauge vitrectomy. Am J Ophthalmol 2005;139:831–836.
4.
Yang SJ, Yoon SY, Kim JG, Yoon YH: Transconjunctival sutureless vitrectomy for the treatment of vitreoretinal complications in patients with diabetes mellitus. Ophthalmic Surg Lasers Imaging 2009;40:461–466.
5.
Von Fricken MA, Kunjukunju N, Weber C, Ko G: 25-Gauge sutureless vitrectomy versus 20-gauge vitrectomy for the repair of primary rhegmatogenous retinal detachment. Retina 2009;29:444–450.
6.
Kychenthal A, Dorta P: 25-gauge lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Retina 2008;28:S65–S68.
7.
Kadonosono K, Yamakawa T, Uchio E, Yanagi Y, Tamaki Y, Araie M: Comparison of visual function after epiretinal membrane removal by 20-gauge and 25-gauge vitrectomy. Am J Ophthalmol 2006;142:513–515.
8.
Rizzo S, Genovesi-Ebert F, Murri S, Belting C, Vento A, Cresti F, Manca ML: 25-gauge, sutureless vitrectomy and standard 20-gauge pars plana vitrectomy in idiopathic epiretinal membrane surgery: a comparative pilot study. Graefes Arch Clin Exp Ophthalmol 2006;244:472–479.
9.
Shinoda H, Shinoda K, Satofuka S, Imamura Y, Ozawa Y, Ishida S, Inoue M: Visual recovery after vitrectomy for macular hole using 25-gauge instruments. Acta Ophthalmol 2008;86:151–155.
10.
Oshima Y, Ohji M, Tano Y: Surgical outcomes of 25-gauge transconjunctival vitrectomy combined with cataract surgery for vitreoretinal diseases. Ann Acad Med Singapore 2006;35:175–180.
11.
Mason JO, Colagross CT, Vail R: Diabetic vitrectomy: risks, prognosis, future trends. Curr Opin Ophthalmol 2006;17:281–285.
12.
Shah CP, Ho AC, Regillo CD, Fineman MS, Vader JF, Brown GC: Short-term outcomes of 25-gauge vitrectomy with silicone oil for repair of complicated retinal detachment. Retina 2008;28:723–728.
13.
Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M, Tano Y: Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009;116:927–938.
14.
Ishida M, Takeuchi S: Long-term results of vitrectomy for complications of proliferative diabetic retinopathy. Nippon Ganka Gakkai Zasshi 2001;105:457–462.
15.
Smiddy WE, Feuer W, Irvine WD, Flynn HW Jr, Blankenship GW: Vitrectomy for complications of proliferative diabetic retinopathy: functional outcomes. Ophthalmology 1995;102:1688–1695.
16.
Nakazawa M, Kimizuka Y, Watabe T, Kato K, Watanabe H, Yamanobe S, Arakawa A, Tamai K: Visual outcome after vitrectomy for diabetic retinopathy: a five-year follow-up. Acta Ophthalmol 1993;71:219–223.
17.
Schiff WM, Barile GR, Hwang JC, Tseng JJ, Cekiç O, Del Priore LV, Turano MR, Chang S: Diabetic vitrectomy: influence of lens status upon anatomic and visual outcomes. Ophthalmology 2007;114:544–550.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.